Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EKR Therapeutics Inc.

Division of Chiesi Farmaceutici SPA

Latest From EKR Therapeutics Inc.

Otonomy appoints new chief commercial officer

Otonomy, a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for diseases and disorders of the inner and middle ear, has named Anthony J Yost chief commercial officer. Most recently Mr Yost was chief commercial officer for specialty pharma companies Prometheus Laboratories and EKR Therapeutics. Prior to this he was general manager for the Western US operating unit of Novartis Pharmaceuticals, where he led commercial operations totaling more than 600 employees generating annual revenues in excess of $600m.


Special Cornerstone committee will consider Chiesi buyout as profit-loss ratio stagnates

Cornerstone Therapeutics formed a special committee with five independent directors to develop a response to the Cary, North Carolina-based company's largest shareholder – the Chiesi Group of Parma, Italy – which wants to acquire the 40% of Cornerstone stock that it does not already own and take the US firm private.

Orthopedics Respiratory

Chiesi Prepared To Pay Cash For Remaining 40% Of Cornerstone

Italian pharmaceutical company Chiesi is looking to buy up the remainder of Cornerstone Therapeutics, a company that already markets Chiesi’s products in the U.S. and is financially linked with the company.

BioPharmaceutical Business Strategies

Cornerstone taps Chiesi link as it hones hospital focus with anti-infective

Cornerstone Therapeutics' stock price ticked slightly higher on 8 November, but closed down 0.6% on news that the Cary, North Carolina-based company licensed exclusive US rights to Chiesi Farmaceutici's recently approved Bethkis (tobramycin inhalation solution) to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Orthopedics Respiratory
See All

Company Information

  • Industry
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Chiesi Farmaceutici SPA
  • Senior Management
  • John E Bailye, Pres. & CEO
    Bill McKee, COO & CFO
    Jon Zwinski, SVP, Sales
    Bryan Stuart, Chief, Corp. Dev.
  • Contact Info
  • EKR Therapeutics Inc.
    Phone: (877) 435-2524
    1545 US Hwy 206
    3rd Fl.
    Bedminster, NJ 07921